Last reviewed · How we verify
EG-MCV4
At a glance
| Generic name | EG-MCV4 |
|---|---|
| Also known as | Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine |
| Sponsor | EyeGene Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EG-MCV4 CI brief — competitive landscape report
- EG-MCV4 updates RSS · CI watch RSS
- EyeGene Inc. portfolio CI